ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ ViiV Healthcare to present long-term safety and efficacy data for 2-drug regimen
Data presented may shift the treatment paradigm to 2-drug regimens (2DRs) for people living with HIV

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders will be presenting 25 abstracts during the HIV Glasgow 2020 congress, being held virtually 5-8 October.

The research will be presented from across its diverse portfolio of late-stage pipeline and licensed HIV treatments as well as findings from one of the largest, global, HIV patient-reported outcomes studies to date.

Key data presentations will include:
GEMINI 144-week and TANGO 96-week pivotal trial data that build upon the existing efficacy and safety profile of 2-drug regimen dolutegravir plus lamivudine in treatment naïve adults with HIV-1 and Dovato (dolutegravir/lamivudine) in virologically suppressed adults with HIV-1 STAT 24-week data which evaluated Dovato for rapid initiation of treatment after diagnosis in adults with HIV-1.

FLAIR 124-week findings for long-acting investigational cabotegravir and rilpivirine that further define its efficacy and safety profile, and analysis from the Phase 3 clinical development programme on factors influencing viral response to long-acting cabotegravir and rilpivirine, as well as an analysis of ATLAS-2M 48-week data of key outcomes in women, an often-under-represented population in clinical trials. Positive Perspectives Wave 2 data exploring gaps in achieving optimal self-rated health; challenges of a new HIV diagnosis in old age; self-care and involvement in HIV care.

Kimberly Smith, Head of Research & Development, ViiV Healthcare, said: “The advances we will be presenting from across the portfolio reflect our continued commitment to addressing the challenges of HIV and delivering therapies that really make a difference in people’s lives. Dovato has already delivered impressive safety and efficacy results for both treatment-naïve and treatment-experienced adults living with HIV. The new long-term results presented at Glasgow will go even further to characterise the durability of and resistance profile for this treatment. We’re excited to participate in the congress and share our latest findings with the community.”

Tags : #LatestPharmaNewsSep30 #LatestGskNewsSep30 #HIVGlasgow2020congress #LatestHIVTreatment #2drugregimenHIV

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026